JP2024533291A5 - - Google Patents
Info
- Publication number
- JP2024533291A5 JP2024533291A5 JP2024515026A JP2024515026A JP2024533291A5 JP 2024533291 A5 JP2024533291 A5 JP 2024533291A5 JP 2024515026 A JP2024515026 A JP 2024515026A JP 2024515026 A JP2024515026 A JP 2024515026A JP 2024533291 A5 JP2024533291 A5 JP 2024533291A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- unsubstituted
- pharmaceutical composition
- composition according
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163241891P | 2021-09-08 | 2021-09-08 | |
| US63/241,891 | 2021-09-08 | ||
| PCT/EP2022/058574 WO2023036473A1 (en) | 2021-09-08 | 2022-03-31 | Combination drug therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533291A JP2024533291A (ja) | 2024-09-12 |
| JP2024533291A5 true JP2024533291A5 (enExample) | 2025-03-25 |
Family
ID=81325378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024515026A Pending JP2024533291A (ja) | 2021-09-08 | 2022-03-31 | 併用薬物療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240366655A1 (enExample) |
| EP (1) | EP4398871A1 (enExample) |
| JP (1) | JP2024533291A (enExample) |
| KR (1) | KR20240052775A (enExample) |
| AU (1) | AU2022342266B2 (enExample) |
| CA (1) | CA3231021A1 (enExample) |
| WO (1) | WO2023036473A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| JP2023539113A (ja) | 2020-08-18 | 2023-09-13 | サイビン アイアールエル リミテッド | フェネチルアミン誘導体、組成物およびその使用方法 |
| KR20240013170A (ko) | 2021-05-25 | 2024-01-30 | 아타이 테라퓨틱스, 인크. | 신규 n,n-디메틸트립타민 염 및 결정질 염 형태 |
| IL309210A (en) | 2021-06-09 | 2024-02-01 | Atai Therapeutics Inc | Parent drugs and conjugates of dimethyltryptamine |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| MX2024008691A (es) * | 2022-01-14 | 2024-07-19 | Cybin Irl Ltd | Composiciones y metodos de triptamina. |
| GB202214721D0 (en) * | 2022-10-06 | 2022-11-23 | Rewire Therapeutics Ltd | A treatment for mental disorders |
| AU2024263322A1 (en) * | 2023-04-28 | 2025-11-13 | The United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for treating post-traumatic stress disorder |
| US12303503B1 (en) | 2023-11-16 | 2025-05-20 | Biobina Llc | Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain |
| AU2024397012A1 (en) * | 2023-12-15 | 2026-07-30 | 10763942 Canada Inc. (Dba. Purminds Neuropharma) | Heterocyclic compounds and methods of preparation thereof |
| WO2025170990A1 (en) * | 2024-02-06 | 2025-08-14 | Atai Therapeutics, Inc. | Controlled transmucosal release of dmt in combination with a monoamine oxidase inhibitor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| US7267121B2 (en) | 2004-04-20 | 2007-09-11 | Aerogen, Inc. | Aerosol delivery apparatus and method for pressure-assisted breathing systems |
| US11622948B2 (en) * | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| DK3927338T3 (da) * | 2019-02-22 | 2025-01-06 | Gh Res Ireland Limited | Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser |
| US12616706B2 (en) * | 2019-03-07 | 2026-05-05 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| KR20220008824A (ko) * | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| WO2021003467A1 (en) * | 2019-07-04 | 2021-01-07 | Sw Holdings, Inc. | Metered dosing compositions and methods of use of psychedelic compounds |
| RU199823U1 (ru) | 2020-06-10 | 2020-09-21 | Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий | Устройство для лечения бронхолегочных заболеваний |
| CA3212065A1 (en) * | 2021-03-15 | 2022-09-22 | James Gilligan | Improved methods for the use of psychedelics |
-
2022
- 2022-03-31 AU AU2022342266A patent/AU2022342266B2/en active Active
- 2022-03-31 JP JP2024515026A patent/JP2024533291A/ja active Pending
- 2022-03-31 CA CA3231021A patent/CA3231021A1/en active Pending
- 2022-03-31 EP EP22716971.1A patent/EP4398871A1/en active Pending
- 2022-03-31 KR KR1020247008355A patent/KR20240052775A/ko active Pending
- 2022-03-31 US US18/688,125 patent/US20240366655A1/en active Pending
- 2022-03-31 WO PCT/EP2022/058574 patent/WO2023036473A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025510942A5 (enExample) | ||
| JP2024540282A5 (enExample) | ||
| JP2024522065A5 (enExample) | ||
| JP2023540017A5 (enExample) | ||
| IL297492A (en) | Deuterated tryptamine derivatives and methods of use | |
| JP2023544724A5 (enExample) | ||
| CN1122018C (zh) | 作为药用活性成分的6－二甲氨基甲基－1－苯基环己烷化合物 | |
| CN100430394C (zh) | N-[杂芳基(哌啶-2-基)甲基]苯甲酰胺衍生物及其制备方法和它们的治疗应用 | |
| JP2025505745A5 (enExample) | ||
| JP2021519267A5 (enExample) | ||
| CN100575334C (zh) | 取代的2-二烷基氨基烷基联苯衍生物 | |
| JP2013544850A5 (enExample) | ||
| JP2007508361A5 (enExample) | ||
| JP2007516941A5 (enExample) | ||
| JP2008524262A5 (enExample) | ||
| JP2002523491A5 (enExample) | ||
| JP2002523508A5 (enExample) | ||
| JP2011509297A5 (enExample) | ||
| JP2009500425A5 (enExample) | ||
| JP2002525280A5 (enExample) | ||
| CN1805956A (zh) | 苯并咪唑衍生物、含有它们的组合物、它们的制备以及它们的用途 | |
| JP2025502208A5 (enExample) | ||
| CA2374668A1 (en) | New pharmaceutical combinations for nos inhibitors | |
| JP2008502651A (ja) | モノアミン神経伝達物質再取込み阻害剤としての、新規アルキル置換ピペリジン誘導体及びその使用 | |
| CN1307574A (zh) | 作为5－羟色胺能药物的吲哚基衍生物 |